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Abstract
Intravenous immunoglobulin (IVIG) is derived from donated plasma used to treat
immune deficiency, autoimmune, and inflammatory disorders. Adverse effects occur
in 5-15% of patients with hemolytic anemia being a delayed reaction. Risk factors for
hemolysis are high-dose infusions (1-2g/kg/day or >100g/day), female sex, and non-O
blood group. Our case involves a 69-year old male presetting with bilateral lower
extremity weakness for 1 year after sustaining a fall, affecting his ability to ambulate
with no bowel or urinary incontinence. MRI revealed spondylotic changes of the
lumbar spine. EMG showed severe bilateral lumbosacral polyradiculopathy with
ongoing denervation and severe sensorimotor peripheral polyneuropathy with axonal
loss. He was diagnosed with chronic inflammatory demyelinating polyneuropathy
(CIDP) and started on high-dose IVIG (0.4mg/kg; 77.6mg) therapy for 5 days. 48
hours after IVIG completion, patient developed acute drop in hemoglobin (9.1 g/dL to
7.0 g/dL) that continued to down-trend (5.7 g/dL). Type and screen was AB positive.
Labs were significant for elevated absolute reticulocyte count (141.5 K/uL),
reticulocyte percentage (6.1%), and LDH (321 IU/L) while haptoglobin was low
(<30.0 mg/dL), consistent with hemolytic anemia. Direct antiglobulin anti-IgG
coombs test was positive and anti-complement negative, consistent with
immunohemolytic anemia. He was supported with blood transfusion and continued on
high-dose Prednisone (1mg/kg/day) for 3 months. Antibodies present in IVIG product
react with RBC antigens predominantly of the ABO blood group, causing
intravascular hemolysis. Although IVIG induced hemolysis is typically mild and selflimiting, it can often go undetected and prescribers should be aware.

Clinical Course
• On hospital day 8, Hgb noted to fall from 9.1 to 7.0 g/dl
• No signs of bleeding was noted, and patient had been tolerating
physical therapy well
• Internal Medicine and Hematology were consulted
• Laboratory work-up was consistent with an IgG mediated
hemolytic process with component of iron deficiency
• Reticulocyte studies showed hypoproliferation
–Reticulocyte index 0.95
• Pathology review of the peripheral blood showed no abnormal
cells
• Patient received 2 units pRBC on hospital day 11 for Hgb 5.7 g/dl
• Patient started on Prednisone 80 mg daily for 3-month course

Hematologic Lab Values

Patient Presentation
• 69-year old male admitted to the neurology unit from clinic for
worsening lower extremity weakness
• MRI, EMG, and LP were performed, and the patient diagnosed
with CIDP
• Patient initiated on IVIG therapy, received doses on hospital day
3-8
• Patient was planned for discharge to inpatient rehabilitation
following IVIG

Figure 1. CBC data. Column 1- on admission. Column 2-4 During IVIg treatment. Columns 5-8 Days
following IVIg. All hemoglobin values are in g/dl.

• Intravenous immunoglobulin (IVIG) is derived from donated
plasma used to treat immune deficiency, autoimmune, and
inflammatory disorders.
• Adverse effects are typically mild and include malaise, headache,
fever, chills, and flushing
• More serious complications are rare and include renal failure,
transfusion reactions, and thrombosis
• Adverse effects can be mitigated by slow infusion, premedicating
with NSAIDS or steroids, and using subcutaneous formulations of
IVIG

• Adverse effects with IVIG occur in 5-15% of patients with
hemolytic anemia being a delayed reaction. Risk factors for
hemolysis are high-dose infusions (1-2g/kg/day or
>100g/day), female sex, and non-O blood group
• Antibodies present in IVIG product react with RBC
antigens predominantly of the ABO blood group, causing
intravascular hemolysis.
• Although IVIG induced hemolysis is typically mild and
self-limiting, it can often go undetected and prescribers
should be aware.
• onset of hemolysis ranged from 12 hours to 10 days, and
the mean decrease in hemoglobin was 3.2 g/dL

Conclusion
• IVIG induced hemolytic anemia is an uncommon event and often
clinically mild
• Providers should maintain a higher index of suspicion in patients
with new anemia on IVIG therapy, especially in those receiving
higher doses
• IVIG induced hemolytic anemia is managed supportively and has
a good prognosis
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Figure 2. Direct Antiglobulin test results

Patient Outcome
• Required 2 units packed RBC inpatient, with appropriate recovery
and stability following
• IV iron infusion provided inpatient
• Patient discharged to subacute rehabilitation on hospital day 14
• Discharged on prednisone for bone marrow support, CIDP
management
• Hemoglobin had recovered to 9.5 g/dL on day of discharge
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